Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA.
Transfus Med Hemother. 2014 Nov;41(6):431-5. doi: 10.1159/000369513. Epub 2014 Nov 14.
Red blood cell (RBC) alloimmunization occurs in approximately 30% of transfused sickle cell disease patients compared to 2-5% of all transfusion recipients. Because RBC transfusion is an important part of therapy in sickle cell disease, the need for additional antigen matching once alloimmunization occurs is problematic and leads to therapeutic limitations. Thus, identification of risk factors would benefit this patient population. Genome-wide analyses, in particular, methods which take into account genetic ancestry such as admixture mapping, could identify molecular markers which could be used to identify immune responders to transfusion.
与所有输血接受者的 2-5%相比，约 30%的接受输血的镰状细胞病患者会发生红细胞 (RBC) 同种免疫。由于 RBC 输血是镰状细胞病治疗的重要组成部分，因此一旦发生同种免疫，需要额外的抗原匹配会带来治疗上的限制。因此，确定风险因素将使这一患者群体受益。全基因组分析，特别是考虑到遗传背景（如混合映射）的方法，可以识别出可用于识别输血免疫反应者的分子标记。
